PDCD1 and cancer: In both chronic infections and in human cancer therapeutics, the blockade of PD-1/PD-L1 interaction with monoclonal antibodies has been demonstrated to reinvigorate exhausted CD8+ T cells, restoring T cell proliferation and the production of effector molecules (perforin, granzymes and cytokines) [14,18].